Gateshead Medicines Management CommitteeDecision Summary

Gateshead Medicines Management Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on Wednesday 14th May 2014.

Classification of Products:

Red = Hospital use only

Amber = Drugs with shared care agreement

Green + = Initiated by Primary or Secondary Care Specialist but can be safely maintained in primary care without ongoing specialist monitoring.

Green = GP & Hospital use. Drugs not classified as Red, Amber or Green + are classified as Green by default

Product / Decision / Comments/notes
Approved / Refused / Deferred
1)Requests deferred from previous meetings
Mini-quofora system / Green+ / Decision: Approved for use in bowel irrigation on advice of colorectal nurse and Mr Mercer Jones only.
2)New Requests
Nutramigen 1 and 2 / Green / Decision: Approved as replacement for pepti-junior in children with cow’s milk allergy.
Generic Combined Oral Contraceptives / Green / Decision:.Generic COCs made by Mornigside Healthcare and Consilient Healthcare approved as alternatives to branded products. To be prescribed by brand name to avoid confusion.
3)New formulations & extensions to use
None received
4)Products considered by NTAG
None received
5)Products considered by NECDAG
None received
6)Products considered by NICE
TA307 – Colorectal cancer (metastatic) - aflibercept /  / Not approved by NICE.
TA308 – Vasculitis (antineutrophil cytoplasmic antibody associated) – rituximab (with corticosteroids) / Red / Approved in line with NICE TAG. See also NHS England Comissioning Circular
TA309 – Lung cancer - pemetrexed /  / Not approved by NICE.
TA310 – Lung cancer – afatinib / Red / Approved in line with NICE TAG.
TA311 – Multiple myeloma – bortezomib (induction therapy) / Red / Approved in line with NICE TAG.
7)Appeals against earlier decisions by GMMC
None received
8)Miscellaneous decisions by GMMC
None
9)NHS England Commissioning Circulars
SSC1415 – Repatiration of Cystic fibrosis /  / Noted not applicable to GHFNT as CF services not provided by GHFNT.
SSC1417 – Hormone therapy for gender dysphoria /  / Noted not applicable to GHFNT as gender dysphoria services not provided by GHFNT.
SSC1419 - Sofosbuvir / Red / Noted not applicable to GHFNT as only for use in specialist centres for treatment of Hep C.
SSC1422 – Rituximab in ANCA vasculatis / Red / As per NICE TA308
SSC1423 – Multiple myeloma – bortezomib (induction therapy) / Red / As per NICE TA311

Page 1 of 2

GMMC Decision Summary 14.5.14